Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myeloma.
Karthick Raja
KR
Muthu Raja
Lucie
L
Kovarova
Roman
R
Hajek
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015331:Cohort Studies; D003907:Dexamethasone / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006801:Humans; D000077269:Lenalidomide; D018655:Lymphocyte Count; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives; D016896:Treatment Outcome
D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide